INTELLIGENT ONCOLOGY
choose a different vision
Recent Releases
CHOSA Oncology resolves on directed and rights issues of units
CHOSA issues units totalling SEK 19.9M to fund operations and reach value-enhancing milestones over the next 12 months.
CHOSA Oncology Presents Aktiedagarna Stockholm
CHOSA Oncology presents its precision medicine approach to cancer treatment at Aktiedagarna (11 June 2025), highlighting our innovative strategies and upcoming milestones.
CHOSA Oncology invites investors to two upcoming presentations
Join CHOSA’s June events to learn about Cisplatin-DRP® progress and our mission to advance precision medicine in oncology.
We provide a safe and more effective solution for patients in need of platin-treatment
Drug Response Predictor
Discover the future of cancer treatment with DRP® — the first-ever biomarker for cisplatin.
Our patented DRP® analyzes 205 key genes in a patient’s tumor to predict their response to cisplatin and carboplatin, enabling personalized treatment plans to oncology patients. We have shown that our innovative technology not only improves survival rates, but also enables doctors to avoid overtreatment of toxic platin to non-responsding patients.
LiPlaCis®
A new formulation of cisplatin in a liposome aimed for a solution to cisplatin treatment by targeting tumors directly, reducing harmful side effects. Using a specialized liposome delivery system, LiPlaCis® releases cisplatin precisely where it's needed most—at the tumor site—providing safer and more effective cancer care.
Key Opinion Leaders
We’re honored by the strong support of seven prominent Key Opinion Leaders (KOLs) in the fields of lung, breast, bladder, and endometrial cancer. Their endorsement enhances the credibility of our DRP® and advances our mission toward precision oncology.
“We need to figure out how to select the right treatment to the right patients. So that is where the future goes. We are leaving the concept of one size fits all.”
Dr. Fred Hirsch